Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Factors Affecting Erythropoiesis

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Hormonal Regulation of Blood Pressure

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...

Overview of Hematopoiesis

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013

Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013

Same author

Colesevelam: a new and improved bile acid sequestrant?

Current pharmaceutical design·2013

Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013

Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013

Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013

Search research articles

Related Experiment Video

Updated: May 28, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Erythropoietin update 2011.

Mariusz Kowalczyk¹, Maciej Banach, Dimitri P Mikhailidis

¹Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland.

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

|November 1, 2011

Summary

Erythropoietin (EPO) traditionally aids red blood cell production but may have broader protective roles beyond hematopoiesis. Clinical evidence for these non-hematopoietic benefits of EPO is still emerging.

More Related Videos

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Related Experiment Videos

Last Updated: May 28, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Area of Science:

Hematology
Molecular Biology
Pharmacology

Background:

Erythropoietin (EPO) is primarily known as a hematopoietic cytokine regulating erythroid progenitor cells.
Recent discoveries show EPO production in novel sites and widespread EPO receptor (EPO-R) distribution in various tissues, including neural and cardiovascular systems.
This suggests potential pleiotropic, non-hematopoietic functions of EPO.

Purpose of the Study:

To provide a comprehensive overview of erythropoietin (EPO) and its derivatives.
To explore the potential non-hematopoietic, protective actions of EPO suggested by preclinical data.
To critically assess the clinical evidence supporting these broader EPO functions.

Main Methods:

Literature review of preclinical and clinical studies on erythropoietin (EPO).
Analysis of data regarding EPO production sites and EPO receptor distribution.
Synthesis of findings on EPO's hematopoietic and non-hematopoietic effects.

Main Results:

Preclinical studies indicate protective, non-hematopoietic effects of EPO across various tissues.
Clinical data regarding these non-hematopoietic properties of EPO are more equivocal.
The article reviews the current understanding of EPO's diverse biological activities.

Conclusions:

Erythropoietin (EPO) exhibits potential pleiotropic actions beyond its classical hematopoietic role.
While preclinical data support non-hematopoietic protective functions, clinical validation remains a key area of investigation.
Further research is needed to fully elucidate the therapeutic potential of EPO and its derivatives in non-hematological conditions.